“CD20×CD3 Bispecific Antibodies in Relapsed/Refractory B-Cell Lymphomas: Recent Phase III Evidence Durability, and Safety”, joms, vol. 21, no. 2, pp. 30–35, Sep. 2026, doi: 10.51984/szn7cg42.